Biotech & Pharma
Health Tech
Politics
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Nicholas Florko Nov. 23, 2021
WASHINGTON — Robert Califf, President Biden’s choice to lead the Food and Drug Administration, earned $2.7 million as an executive at Google’s life science arm Verily, and he holds between $1 million and $5 million in equity in the company, according to a recent financial statement filed with the White House.
Califf is also coming into the FDA’s top job with a massive stock portfolio. His financial statement lists roughly 30 companies in which he owns more than $100,000 worth of stock as part of a retirement account. His holdings include between $250,000 and $500,000 worth of stock in the pharmaceutical giants Bristol Myers Squibb and Amgen and between $100,000 and $250,000 in Gilead.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
Washington Correspondent
Nicholas Florko reports on the the intersection of politics and health policy. He is the author the newsletter “D.C. Diagnosis.”
healthtech
Joe Biden
pharmaceuticals
STAT+
White House
This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Rachel Cohrs
By Lev Facher
advertisement
By Angus Chen
By Rachel Cohrs
By Rachel Cohrs
Reporting from the frontiers of health and medicine
